1-5 of 5
Yelak Biru
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Overcoming Barriers to Novel Combination Therapy in Multiple Myeloma (MM): Oncocollective Insights into Improving Patient Outcomes in Europe

Ya-Chen Tina Shih, Gilberto Morgan, Yelak Biru, Eva Susanne Dietrich, Lars Holger Ehlers, Lise-Lott Eriksson, Manuel García -Goñi, Wolfgang Greiner, Lars-Ake Levin, Maarten Postma, Celine Fernandez, Krupa Paranjpe, Hilary Hansen, Alvaro Lopez Galnares, M. B. Caschetta, Randi Goeckeler, Edwin Lee
Journal: Blood
Blood (2024) 144 (Supplement 1): 6973.
https://doi.org/10.1182/blood-2024-205091
Published: 2024
Journal Articles

Examining Discrepancies in Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Novel Therapies across Diverse Clinical Landscapes: An International Prospective Study

Sikander Ailawadhi, Yelak Biru, Solène Clavreul, Maite San Miguel, Nicolas Cormier, Anna Sato, Cathy Zeanah, James Farrell, Erinn Hoag Goldman, Rakesh Popat
Journal: Blood
Blood (2024) 144 (Supplement 1): 3658.
https://doi.org/10.1182/blood-2024-208007
Published: 2024
Journal Articles

Frontiers in Myeloma: Barriers to Clinical Trial Participation in Multiple Myeloma

Martin F Kaiser, Saba Ul-Hasan, Jack Lewis, Federica Mirto, Alicia O'Neill, Elise Gamertsfelder, Yelak Biru
Journal: Blood
Blood (2024) 144 (Supplement 1): 3788.
https://doi.org/10.1182/blood-2024-208431
Published: 2024
Journal Articles

Cytokine Release Syndrome: The Patient, Caregiver and Healthcare Professional Experience

Janelle Soong, Giuseppe De Carlo, Naziah Lasi-Tejani, Sumanjit K. Sethi, Natacha Bolaños, Martine Elias, Yelak Biru, Solène Clavreul, G. Scott Chandler, Klaus Finzler, Yann Nouet, Antonio Giuseppe Del Santo
Journal: Blood
Blood (2023) 142 (Supplement 1): 3718.
https://doi.org/10.1182/blood-2023-174207
Published: 2023
Journal Articles

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Luciano J. Costa, MD PhD, Saurabh Chhabra, MD, Kelly N. Godby, MD, Eva Medvedova, MD, Robert F. Cornell, MD MS, Aric C. Hall, MD, Rebecca W. Silbermann, MD, Racquel Innis-Shelton, MD, Binod Dhakal, MBBS, Diego DeIdiaquez, MD, Pamela Hardwick, RN, Yelak Biru, James L. Omel, MD, Parameswaran Hari, MBBS, MD, Natalie Scott Callander, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 860.
https://doi.org/10.1182/blood-2019-123170
Published: 2019